JP2022524008A - うつ病の治療のためのエスケタミン - Google Patents

うつ病の治療のためのエスケタミン Download PDF

Info

Publication number
JP2022524008A
JP2022524008A JP2021552724A JP2021552724A JP2022524008A JP 2022524008 A JP2022524008 A JP 2022524008A JP 2021552724 A JP2021552724 A JP 2021552724A JP 2021552724 A JP2021552724 A JP 2021552724A JP 2022524008 A JP2022524008 A JP 2022524008A
Authority
JP
Japan
Prior art keywords
esketamine
treatment
patient
administered
approved
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021552724A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022524008A5 (enExample
Inventor
シン，ジャスカラン
ダリー，エラ
Original Assignee
ヤンセン ファーマシューティカルズ，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカルズ，インコーポレーテッド filed Critical ヤンセン ファーマシューティカルズ，インコーポレーテッド
Publication of JP2022524008A publication Critical patent/JP2022524008A/ja
Publication of JP2022524008A5 publication Critical patent/JP2022524008A5/ja
Priority to JP2024157984A priority Critical patent/JP2025003983A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021552724A 2019-03-05 2020-02-18 うつ病の治療のためのエスケタミン Withdrawn JP2022524008A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024157984A JP2025003983A (ja) 2019-03-05 2024-09-12 うつ病の治療のためのエスケタミン

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962814274P 2019-03-05 2019-03-05
US201962813767P 2019-03-05 2019-03-05
US62/814,274 2019-03-05
US62/813,767 2019-03-05
PCT/IB2020/051344 WO2020178653A1 (en) 2019-03-05 2020-02-18 Esketamine for the treatment of depression

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024157984A Division JP2025003983A (ja) 2019-03-05 2024-09-12 うつ病の治療のためのエスケタミン

Publications (2)

Publication Number Publication Date
JP2022524008A true JP2022524008A (ja) 2022-04-27
JP2022524008A5 JP2022524008A5 (enExample) 2023-03-02

Family

ID=72338604

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021552724A Withdrawn JP2022524008A (ja) 2019-03-05 2020-02-18 うつ病の治療のためのエスケタミン
JP2024157984A Pending JP2025003983A (ja) 2019-03-05 2024-09-12 うつ病の治療のためのエスケタミン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024157984A Pending JP2025003983A (ja) 2019-03-05 2024-09-12 うつ病の治療のためのエスケタミン

Country Status (11)

Country Link
US (4) US20230117657A1 (enExample)
EP (1) EP3934632A4 (enExample)
JP (2) JP2022524008A (enExample)
CN (1) CN114126595A (enExample)
AU (1) AU2020231172A1 (enExample)
BR (1) BR112021017457A2 (enExample)
CA (1) CA3131929A1 (enExample)
IL (2) IL318198A (enExample)
MA (1) MA55218A (enExample)
MX (1) MX2021010683A (enExample)
WO (1) WO2020178653A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2907692T3 (es) 2017-12-29 2022-04-26 Celon Pharma Sa Composición de ketamina de polvo seco para su administración por vía pulmonar en la depresión resistente al tratamiento
JP2022524008A (ja) * 2019-03-05 2022-04-27 ヤンセン ファーマシューティカルズ，インコーポレーテッド うつ病の治療のためのエスケタミン
JP2022548233A (ja) * 2019-09-13 2022-11-17 ヤンセン ファーマシューティカルズ，インコーポレーテッド エスケタミンの鼻腔内投与
JP2023511370A (ja) * 2020-01-22 2023-03-17 シーロス セラピューティクス， インコーポレイテッド Ｎｍｄａ拮抗薬の副作用の低減
CN116744922A (zh) * 2020-12-04 2023-09-12 诺华股份有限公司 Nr2b-nmda受体nam在治疗抑郁症中的剂量方案
US20240261236A1 (en) * 2021-05-14 2024-08-08 Seelos Therapeutics, Inc. Methods of using nmda receptor antagonists
IL321485A (en) * 2022-12-14 2025-08-01 Luminous Mind Inc Treatment of psychological symptoms affecting other medical conditions (PFAOMC)
EP4687860A1 (en) * 2023-03-24 2026-02-11 Janssen Pharmaceutica NV Esketamine for use in the treatment of depression

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018515557A (ja) * 2015-05-20 2018-06-14 ヤンセン ファーマシューティカ エヌ．ベー． うつ病を治療するための方法及びキット

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH535201A (de) 1969-12-19 1973-03-31 Bristol Myers Co Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren
JPS632932A (ja) 1986-06-23 1988-01-07 Teijin Ltd 経鼻投与用粉末状組成物
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US4994467A (en) 1989-05-31 1991-02-19 Zimmerman Andrew W Treating autism and other developmental disorders in children with NMDA receptor antagonists
DE4312016A1 (de) 1993-04-13 1994-10-20 Goedecke Ag Stabile Ketamin-Lösungen
US5543434A (en) 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
DK0814790T3 (da) 1995-02-24 2003-11-10 Stuart L Weg Indgivelse af ketamin med henblik på afgiftning
CA2230690C (en) 1995-08-30 2008-12-23 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
FR2739294B1 (fr) 1995-09-29 1998-01-16 Lhd Lab Hygiene Dietetique Embout nasal de securite
DE19619665C2 (de) 1996-05-15 2001-03-08 Goedecke Ag Racemattrennung von Ketamin
DE19723133A1 (de) 1997-06-03 1998-12-10 Caideil M P Teoranta Tourmakea Austragvorrichtung für Medien
FR2764807B1 (fr) 1997-06-18 1999-08-20 Valois Sa Dispositif de distribution nasale d'un produit fluide ou pulverulent
RU2224523C2 (ru) 1998-07-24 2004-02-27 Сео Хонг Ю Водный раствор, содержащий желчную кислоту, и способ его получения
US6599883B1 (en) 1998-10-30 2003-07-29 Nastech Pharmaceutical Company, Inc. Nasal delivery of xylitol
US6176242B1 (en) 1999-04-30 2001-01-23 Medtronic Inc Method of treating manic depression by brain infusion
US6017961A (en) 1999-07-08 2000-01-25 Flores; John Anthony Ketamine and n-butyl-p-aminobezoate in PLO
EP1103256A1 (de) 1999-11-26 2001-05-30 Claudius Dr. med. Böck Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom
EP1328214A4 (en) 2000-09-20 2009-07-29 Shahinian Lee Jr NASAL, INHALABLE AND LOCAL OPHTHALMIC PREPARATIONS AND MEDICATIONS WITH SPONTANEOUS CONSERVATION
US6881731B1 (en) 2000-10-23 2005-04-19 Shanbrom Technologies, Llc Enhancers for microbiological disinfection
CA2529857A1 (en) 2002-07-30 2004-02-05 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
JP2006510618A (ja) 2002-11-18 2006-03-30 ヤウポン セラピューティクス，インコーポレーテッド ノルケタミンおよびケタミン／ノルケタミンプロドラッグの鎮痛的使用
US7687080B2 (en) 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
US20040214215A1 (en) 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US8082173B2 (en) * 2003-05-22 2011-12-20 Cecil Kost Drug sample fulfillment architecture
US20050095277A1 (en) 2003-06-25 2005-05-05 Binnur Ozturk Neuropathy cream
US20040265364A1 (en) 2003-06-25 2004-12-30 Binnur Ozturk Neuropathy cream
WO2005079756A2 (en) 2004-02-13 2005-09-01 Neuromolecular, Inc. Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions
JP5607291B2 (ja) 2004-11-24 2014-10-15 メダ ファーマシューティカルズ インコーポレイテッド アゼラスチンを含む組成物およびその使用方法
US20060223788A1 (en) 2005-03-29 2006-10-05 Cathcart Clifton H Analgesic composition for topical use
JP5026411B2 (ja) 2005-06-01 2012-09-12 エスエイチエル グループ エービー 薬物送達装置
US20060276550A1 (en) 2005-06-03 2006-12-07 Dileep Bhagwat Topical compositions of ketamine and butamben and methods of their use
AU2007229866A1 (en) 2006-03-22 2007-10-04 Mount Sinai School Of Medicine Intranasal administration of ketamine to treat depression
WO2007123945A2 (en) 2006-04-21 2007-11-01 Aradigm Corporation Mechanical single dose intrapulmonary drug delivery devices
US20090306137A1 (en) 2006-05-22 2009-12-10 Wolfgang Curt D Treatment for depressive disorders
DE102007009888A1 (de) 2007-02-28 2008-09-04 Hermann, Holger Lars, Dr. Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
BRPI0809843A2 (pt) 2007-04-26 2014-09-23 Auspex Pharmaceuticals Inc "composto, composição farmacêutica e uso de um composto"
US7745665B2 (en) * 2007-06-04 2010-06-29 Auspex Pharmaceuticals, Inc. Substituted phenethylamines
WO2009131794A1 (en) 2008-03-27 2009-10-29 University Of Kentucky Research Foundation Opioid-ketamine and norketamine codrug combinations for pain management
NZ588895A (en) 2008-05-13 2012-07-27 Clarassance Inc Recombinant human CC10 (rhCC10 aka uteroglobin) and compositions thereof for use in the treatment of nasal rhinitis
US20110038807A1 (en) 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder
US20120225949A1 (en) 2009-08-14 2012-09-06 Demitri Papalos Compositions and methods for treating bipolar disorder
EP2992877A1 (en) 2010-06-15 2016-03-09 Grünenthal GmbH Pharmaceutical combination for the treatment of pain
WO2013003669A2 (en) 2011-06-30 2013-01-03 University Of South Florida Compositions, methods of use, and methods of treatment
WO2013056229A1 (en) 2011-10-14 2013-04-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services The use of (2r, 6r)-hydroxynorketamine, (s)-dehydronorketamine and other stereoisomeric dehydro and hydroxylated metabolites of (r,s)- ketamine in the treatment of depression and neuropathic pain
RU2622082C2 (ru) 2011-11-14 2017-06-09 Нестек С.А. Анализы и способы выбора режима лечения пациента с депрессией
US20130209585A1 (en) 2012-02-13 2013-08-15 Stanley Kim Topical NMDA Antagonist Formulations for the Treatment of Peripheral Neuropathy
WO2013138322A1 (en) * 2012-03-12 2013-09-19 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
AU2016203771A1 (en) 2012-03-13 2016-06-23 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
EP2830604A4 (en) 2012-03-30 2015-08-19 Gen Hospital Corp COMPOSITIONS WITH SCOPOLAMINE AND KETAMINE FOR THE TREATMENT OF DEPRESSIONS
US20140079740A1 (en) 2012-08-02 2014-03-20 ClinPharm Support GmbH Oral transmucosal adminstration forms of s-ketamine
KR20150096370A (ko) 2012-08-23 2015-08-24 스튜어트 엘. 웨그 항불안제 조성물, 제형 및 사용방법
FR2994844B1 (fr) 2012-08-31 2015-01-02 Assist Publ Hopitaux De Paris Formulation gelifiante a base de ketamine
NZ619257A (en) 2012-10-08 2015-07-31 Auckland Uniservices Ltd Ketamine derivatives
ES2484068B1 (es) 2013-02-08 2015-04-16 Ana MÍNGUEZ MARTÍ Una composición farmacéutica que contiene ketamina y amitriptilina
US20140274981A1 (en) 2013-03-15 2014-09-18 Janssen Pharmaceutica Nv Pharmaceutical composition of s-ketamine hydrochloride
DK2983787T3 (da) 2013-04-12 2020-01-06 Icahn School Med Mount Sinai Fremgangsmåde til behandling af posttraumatisk stresssygdom
CA2922507C (en) 2013-08-26 2022-07-05 Amorsa Therapeutics, Inc. Single-layer oral dose of neuro-attenuating ketamine
HUE056378T2 (hu) 2013-09-13 2022-02-28 Univ Chiba Nat Univ Corp R-Ketamin és sójának alkalmazása gyógyszerekként
CN103705909A (zh) 2013-12-16 2014-04-09 陈镜伊 一种无痛人流用药
WO2015101693A1 (es) 2013-12-31 2015-07-09 Servicio Andaluz De Salud Composiciones y preparaciones combinadas para el tratamiento de las algias orofaríngeas
EP3094312B1 (en) 2014-01-14 2019-03-13 Children's Hospital Medical Center Compositions comprising ketamine for treating an autism spectrum disorder
PL3287124T3 (pl) 2014-04-17 2023-02-20 Ketabon Gmbh Doustna postać dawkowania ketaminy
MX2016013787A (es) 2014-05-04 2017-07-24 Firmenich & Cie Productos alimenticios y bebidas que estan saborizados.
FR3023188B1 (fr) 2014-07-04 2016-08-19 Aptar France Sas Dispositif de distribution de produit fluide.
KR20170040800A (ko) 2014-08-13 2017-04-13 얀센 파마슈티카 엔.브이. 우울증 치료 방법
AU2015318123A1 (en) 2014-09-15 2017-03-30 Janssen Pharmaceutica Nv Val66Met (SNP rs6265) genotype specific dosing regimens and methods for the treatment of depression
WO2016109427A1 (en) 2014-12-31 2016-07-07 Icahn School Of Medicine At Mount Sinai Method of maintaining the anti-depressant effect of ketamine with lithium
WO2016172672A1 (en) 2015-04-24 2016-10-27 Icahn School Of Medicine At Mount Sinai Method for treating suicidal ideation
CN104798728A (zh) 2015-05-08 2015-07-29 南京中医药大学 产后抑郁动物模型的建立方法及其应用
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
CN107847469A (zh) 2015-06-27 2018-03-27 美国神农制药责任有限公司 氯胺酮透皮递送系统
US20180296478A1 (en) 2016-02-12 2018-10-18 Synergistic Therapeutics, Llc Sublingual antidepressant and antianxiety tablet
US20180042936A1 (en) 2016-03-18 2018-02-15 Genomind, Inc. Maintenance therapy using tianeptine
KR20240011237A (ko) * 2017-12-22 2024-01-25 얀센 파마슈티카 엔브이 우울증 치료를 위한 에스케타민
JP2022524008A (ja) * 2019-03-05 2022-04-27 ヤンセン ファーマシューティカルズ，インコーポレーテッド うつ病の治療のためのエスケタミン

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018515557A (ja) * 2015-05-20 2018-06-14 ヤンセン ファーマシューティカ エヌ．ベー． うつ病を治療するための方法及びキット

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NEUROPSYCHOPHARMACOLOGY, vol. 40, JPN6024009568, 2015, pages 1, ISSN: 0005432207 *

Also Published As

Publication number Publication date
US20220362144A1 (en) 2022-11-17
US11883526B2 (en) 2024-01-30
CA3131929A1 (en) 2020-09-10
EP3934632A1 (en) 2022-01-12
IL286000A (en) 2021-10-31
US20240325296A1 (en) 2024-10-03
WO2020178653A1 (en) 2020-09-10
CN114126595A (zh) 2022-03-01
EP3934632A4 (en) 2022-11-23
AU2020231172A1 (en) 2021-09-23
US20230117657A1 (en) 2023-04-20
US20240277608A1 (en) 2024-08-22
IL318198A (en) 2025-03-01
JP2025003983A (ja) 2025-01-14
BR112021017457A2 (pt) 2021-11-16
MX2021010683A (es) 2021-12-10
MA55218A (fr) 2022-01-12

Similar Documents

Publication Publication Date Title
JP7807870B2 (ja) うつ病の治療のためのエスケタミン
US20240307322A1 (en) Delivery Of Esketamine For The Treatment Of Depression
JP2022524008A (ja) うつ病の治療のためのエスケタミン
ES2879631T3 (es) Pridopidina para el tratamiento de la enfermedad de Huntington
US20240335398A1 (en) Intranasal administration of esketamine
JP2026050474A (ja) Ｎｍｄａ拮抗薬の副作用の低減
JP2024517937A (ja) Ｎｍｄａ受容体拮抗薬の副作用の低減
RU2830614C1 (ru) Интраназальное введение эскетамина
Gerges et al. Oral Aspirin/ketamine versus oral ketamine for emergency department patients with acute musculoskeletal pain
HK40107870A (zh) 用於治疗抑郁症的艾司氯胺酮
AU2010273575A1 (en) Exo-S-mecamylamine method, use, and compound for treatment
Walker et al. Comments on" Dose Response and Dose Equivalence of Antipsychotics" in JCP 2004; 24: 192-208
Davis et al. Reply to" Dosing Equivalency of Second-Generation Antipsychotic Medications"
Davis et al. Reply to Dr. Kerrick Walter and Associates

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220414

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240312

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240612

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240809

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241008

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20250207